An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor

Blood

Volumn 107, Issue 5, 2006, Pages 1864-1871

  Staerk, Judith ^b   Lacout, Catherine ^b   Sato, Takeshi ^b   Smith, Steven O ^b   Vainchenker, William ^b   Constantinescu, Stefan N ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; JANUS KINASE 2; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL JUNCTION; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; ERYTHROID CELL; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 33344455687     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2600     Document Type: Article

References (45)

1. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533-538.
2. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568-571.
3. Solar GP, Kerr WG, Zeigler FC, et al. Role of cmpl in early hematopoiesis. Blood. 1998;92:4-10.
4. Drachman JG, Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci U S A. 1997;94:2350-2355.
5. Miyakawa Y, Oda A, Druker BJ, et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood. 1995;86:23-27.
6. Sattler M, Durstin MA, Frank DA, et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995;23:1040-1048.
7. Miyakawa Y, Oda A, Druker BJ, et al. Thrombopoietin and thrombin induce tyrosine phosphorylation of Vav in human blood platelets. Blood. 1997;89:2789-2798.
8. Oda A, Miyakawa Y, Druker BJ, et al. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood. 1996;88:4304-4313.
9. Onishi M, Mui AL, Morikawa Y, et al. Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer. Blood. 1996;88:1399-1406.
10. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell. 1990;63:1137-1147.
11. Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature. 1990;348:647-649.
12. Watowich SS, Yoshimura A, Longmore GD, Hilton DJ, Yoshimura Y, Lodish HF. Homodimerization and constitutive activation of the erythropoietin receptor. Proc Natl Acad Sci U S A. 1992;89:2140-2144.
13. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J. 1995;14:5569-5578.
14. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198-4200.
15. Alexander WS, Dunn AR. Structure and transcription of the genomic locus encoding murine c-Mpl, a receptor for thrombopoietin. Oncogene. 1995;10:795-803.
16. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood. 1999;94:365-367.
17. Socolovsky M, Dusanter-Fourt I, Lodish HF. The prolactin receptor and severely truncated erythropoietin receptors support differentiation of erythroid progenitors. J Biol Chem. 1997;272:14009-14012.
18. Challier C, Cocault L, Berthier R, et al. The cytoplasmic domain of Mpl receptor transduces exclusive signals in embryonic and fetal hematopoietic cells. Blood. 2002;100:2063-2070.
19. Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell. 2001;7:377-385.
20. Liu X, Constantinescu SN, Sun Y, et al. Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal Biochem. 2000;280:20-28.
21. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495-3503.
22. Klingmuller U, Bergelson S, Hsiao JG, Lodish HF. Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci U S A. 1996;93:8324-8328.
23. Sotiropoulos A, Moutoussamy S, Binart N, Kelly PA, Finidori J. The membrane proximal region of the cytoplasmic domain of the growth hormone receptor is involved in the activation of Stat 3. FEBS Lett. 1995;369:169-172.
24. Storz P, Doppler H, Horn-Muller J, Groner B, Pfizenmaier K, Muller G. A cellular reporter assay to monitor insulin receptor kinase activity based on STAT 5-dependent luciferase gene expression. Anal Biochem. 1999;276:97-104.
25. Eyckerman S, Waelput W, Verhee A, Broekaert D, Vandekerckhove J, Tavernier J. Analysis of Tyr to Phe and fa/fa leptin receptor mutations in the PC12 cell line. Eur Cytokine Netw. 1999;10:549-556.
26. Treisman R. Journey to the surface of the cell: Fos regulation and the SRE. EMBO J. 1995;14:4905-4913.
27. Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell. 2003;12:1239-1250.
28. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8:1327-1338.
29. Liu W, Crocker E, Constantinescu SN, Smith SO. Helix packing and orientation in the transmembrane transmembrane dimer of gp55-P of the spleen focus forming virus. Biophys J. 2005;89:1194-1202.
30. Murakami M, Narazaki M, Hibi M, et al. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A. 1991; 88:11349-11353.
31. Palacios R, Steinmetz M. II-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 1985;41:727-734.
32. Komatsu N, Nakauchi H, Miwa A, et al. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colonystimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res. 1991;51:341-348.
33. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280:27251-27261.
34. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
35. Maguire HC Jr, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol. 1989;16:148-155.
36. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1987;84:7159-7163.
37. Drachman JG, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J. Biol. Chem. 1995;270:4979-4982.
38. McLaughlin S, Smith SO, Hayman MJ, Murray D. An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family. J Gen Physiol. 2005;126:41-53.
39. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A. 2001;98:4379-4384.
40. Abe M, Suzuki K, Inagaki O, Sassa S, Shikama H. A novel MPL point mutation resulting in thrombopoietin-independent activation. Leukemia. 2002;16:1500-1506.
41. van de Geijn GJ, Gits J, Aarts LH, Heijmans-Antonissen C, Touw IP. G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact. Blood. 2004;104:667-674.
42. Jin L, Siritanaratkul N, Emery DW, et al. Targeted expansion of genetically modified bone marrow cells. Proc Natl Acad Sci U S A. 1998;95:8093-8097.
43. Richard RE, Wood B, Zeng H, Jin L, Papayannopoulou T, Blau CA. Expansion of genetically modified primary human hemopoietic cells using chemical inducers of dimerization. Blood. 2000;95:430-436.
44. Millot GA, Vainchenker W, Dumenil D, Svinarchuk F. Differential signalling of NH2-terminal flaglabelled thrombopoietin receptor activated by TPO or anti-FLAG antibodies. Cell Signal. 2004;16:355-363.
45. Elliott S, Lorenzini T, Yanagihara D, Chang D, Elliott G. Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J Biol Chem. 1996;271:24691-24697.